2023 Duke-International Society for Cardiovascular Infectious Diseases (ISCVID) Criteria
This tool is based on the 2023 International Society for Cardiovascular Infectious Diseases criteria.
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Definite IE2–99
- Possible IE1–1
- Rejected0–0
The 2023 Duke-International Society for Cardiovascular Infectious Diseases (ISCVID) Criteria calculates predicting invasive bacterial infection probability and quantifying systemic host response to sepsis. Key inputs include microbiologic major typical. Scores guide administering empiric broad-spectrum antimicrobial regimens, infectious source control, and isolation protocols. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Diagnostic criteria for infective endocarditis, updated from the original Duke criteria with improved sensitivity and specificity.
Clinical Indication
The 2023 Duke-International Society for Cardiovascular Infectious Diseases (ISCVID) Criteria is indicated for bedside clinical practice to support Diagnostic criteria for infective endocarditis, updated from the original Duke criteria with improved sensitivity and specificity.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with suspected sepsis, meningitis, pneumonia, COVID-19, opportunistic infections, or fever of unknown origin. Clinical application is indicated across Infectious disease services, septic shock bays, febrile illness clinics, and isolation units.
Limitations & Contraindications
Timely administration of empiric antibiotic therapy in suspected septic shock must never be delayed for score tabulation.
Clinical Pearls & Action Plan
Blood and site-specific microbiological cultures should be secured prior to administering broad-spectrum antimicrobials.
Diagnostic algorithm based on pathologic criteria (definite if present), major criteria (microbiologic, imaging, surgical), and minor criteria (predisposing conditions, clinical manifestations). Definite IE: 2 major criteria OR 1 major + 3 minor criteria OR 5 minor criteria. Possible IE: 1 major + 1 minor criteria OR 3 minor criteria.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| microbiologic_major_typical | string | No | Microorganisms that commonly cause IE isolated from 2 or more separate blood culture sets |
| microbiologic_major_nontypical | string | No | Microorganisms that occasionally or rarely cause IE isolated from 3 or more separate blood culture sets |
| pcr_positive_coxiella_bartonella_tropheryma | string | No | Positive PCR or nucleic acid-based technique for Coxiella burnetii, Bartonella species, or Tropheryma whipplei from blood |
| coxiella_antibody_titer | string | No | Coxiella burnetii antiphase I IgG antibody titer >1:800, or isolated from single blood culture |
| bartonella_antibody_titer | string | No | Indirect IFA for Bartonella henselae or quintana with IgG titer ≥1:800 |
| imaging_major_echo_ct | string | No | Echocardiography/cardiac CT showing vegetation, perforation, aneurysm, abscess, pseudoaneurysm, or fistula |
| new_valvular_regurgitation | string | No | Significant new valvular regurgitation on echocardiography compared with previous imaging |
| prosthetic_valve_dehiscence | string | No | New partial dehiscence of prosthetic valve compared with previous imaging |
| pet_ct_abnormal_activity | string | No | [18F]FDG PET/CT abnormal metabolic activity involving valve, graft, device leads, or prosthetic material |
| surgical_evidence | string | No | Evidence of IE documented by direct inspection during heart surgery |
| previous_ie | string | No | Previous history of infective endocarditis |
| prosthetic_valve | string | No | Prosthetic valve present |
| previous_valve_repair | string | No | Previous valve repair |
| congenital_heart_disease | string | No | Congenital heart disease |
| significant_regurgitation_stenosis | string | No | More than mild regurgitation or stenosis of any etiology |
| endovascular_cied | string | No | Endovascular cardiac implantable electronic device (CIED) |
| hypertrophic_cardiomyopathy | string | No | Hypertrophic obstructive cardiomyopathy |
| injection_drug_use | string | No | Injection drug use |
| fever | string | No | Fever with documented temperature >38.0°C (100.4°F) |
| vascular_phenomena | string | No | Vascular phenomena (emboli, septic infarcts, mycotic aneurysm, hemorrhage, Janeway lesions) |
| immunologic_phenomena | string | No | Immunologic phenomena (RF+, Osler nodes, Roth spots, glomerulonephritis) |
| positive_blood_cultures_minor | string | No | Positive blood cultures for microorganism consistent with IE but not meeting major criterion |
| positive_sterile_site_culture | string | No | Positive culture/PCR from sterile body site other than cardiac tissue or arterial embolus |
| pet_ct_within_3_months | string | No | Abnormal [18F]FDG PET/CT activity within 3 months of prosthetic material implantation |
| new_regurgitation_auscultation | string | No | New valvular regurgitation on auscultation (if echo not available) |
| pathologic_microorganisms | string | No | Microorganisms identified in vegetation with clinical signs of active endocarditis |
| pathologic_active_endocarditis | string | No | Active endocarditis identified in or on vegetation histologically |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 2–99 | Definite IE | Meets criteria for definite infective endocarditis |
| 1–1 | Possible IE | Meets criteria for possible infective endocarditis |
| 0–0 | Rejected | Does not meet criteria for infective endocarditis |
Evidence-Based References (EBM)
- Fowler VG Jr, Durack DT, Selton-Suty C, et al. The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria. Clin Infect Dis. 2023;77(4):518-526.
- Cahill TJ, Baddour LM, Habib G, et al. Challenges in Infective Endocarditis. J Am Coll Cardiol. 2017;69(3):325-344.
- Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J. 2015;36(44):3075-3128.